KAHR-103

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameKAHR-103
Drug Alias NameCD40-FasL (KAHR)KAHR-103
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionApoptosis-mediating surface antigen FAS stimulantsTumor necrosis factor receptor superfamily member 5 agonists
TargetsTumor necrosis factor receptor superfamily member 5Apoptosis-mediating surface antigen FAS
Therapy Area/IndicationsAutoimmune Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryIsrael
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesKahr Medical
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesKahr Medical
Active IndicationsN/A
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A